Founded in 1954 and headquartered in Greenfield, Indiana, Elanco Animal Health is a global leader in the animal pharmaceutical industry. The company’s core mission is to enhance the health and well-being of animals, both companion and livestock, through innovative products. Elanco develops, manufactures, and markets a range of pharmaceutical drugs aimed at improving animal health and productivity. Serving clients worldwide, Elanco focuses on providing solutions that support both pet owners and food producers.
Notable figures affiliated with Elanco include Chairman R. David Hoover and CEO Jeff Simmons. The company is publicly traded on the NYSE under the ticker ELAN and is a component of the Russell 1000 index. In 2021, Elanco reported revenues of $4.765 billion. Despite facing financial challenges with a net income loss of $0.472 billion in the same year, Elanco continues to make significant strides in the animal health sector, impacting global animal care practices and contributing to the overall well-being of animals around the world.
